4.7 Article

Oncology Patient Interest in the Use of New Technologies to Manage Their Disease: Cross-Sectional Survey

Journal

JOURNAL OF MEDICAL INTERNET RESEARCH
Volume 20, Issue 10, Pages -

Publisher

JMIR PUBLICATIONS, INC
DOI: 10.2196/11006

Keywords

eHealth; app; information and communication technologies; oncology patient

Funding

  1. iPharma (Pharmacy Innovation Center at the Hospital General Universitario Gregorio Maranon) through ERDF [PI13/02056]
  2. European Regional Development Fund ERDF, a way of making Europe

Ask authors/readers for more resources

Background: Information and communication technologies (ICTs) in oncology can revolutionize the medical care of cancer patients. ICTs can promote patients' empowerment and real-time disease monitoring. There is limited information about the impact of ICTs in cancer patients or their level of interest in using these tools for greater management of their condition. Objective: This study aimed to understand the ICT usage profile in hematology-oncology patients to identify their needs and determine their level of interest in these technologies as a means of managing their disease. Methods: A 28-item questionnaire was drawn up by a multidisciplinary team including pharmacists and oncologists. The questions were organized into 3 blocks, which were as follows: block A-sociodemographic characteristics; block B-use of ICTs when searching for health-related information; and block C-usage preferences for health apps. Hematology-oncology patients receiving treatment between May and July 2017 were included. A paper copy of the questionnaire was handed over to patients in either the day hospital or the pharmaceutical care consultancy in pharmacy services. Results: A total of 650 questionnaires were handed out, with a participation of 94.0% (611/650). Patient sociodemographic characteristics were as follows: mean age was 57.8 years (age range: 19-91). Of 611 participants, 40.7% (249/611) had a university education, and 45.1% (276/611) of participants reported their overall state of health to be good. Results from use of ICTs when searching for health-related information were as follows: 87.1% (532/611) of participants were interested in being informed about health-related matters. Of all participants, 75.5% (532/611) sought information from health professionals and 61.3% (375/611) on the internet. Before going to their doctor's appointment, 21.8% (133/611) of patients looked up information about their disease or treatment on the internet. This access to the internet rose to 50.9% (311/611) after their first medical appointment with their oncologist. Usage preferences for health apps were as follows: 82.7% (505/611) had a smartphone, whereas 20.3% (124/611) had a health app installed. Overall, 81.5% (498/611) would use an app if their health professional recommended it to them, but 39.6% (242/611) were not willing to pay for it. Conclusions: The hematology-oncology patients showed a great deal of interest in searching for health-related information by means of ICTs, especially using smartphones and apps. The issues that drew the most interest in terms of apps were appointment management, advice on disease management, and communication with health professionals. Free access to these features and the recommendation by a health professional are important factors when it comes to their use. Therefore, the health care provider is a key element in the recommendation of ICTs, providing their knowledge and experience concerning their correct usage.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

Cristina Villanueva-Bueno, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Alvaro Gimenez-Manzorro, Almudena Ribed, Belen Marzal-Alfaro, Jose Luis Revuelta-Herrero, Eva Gonzalez-Haba, Ana Herranz, Maria Sanjurjo

Summary: Oral antineoplastic agents (OAAs) are high-risk drugs that may increase the risk of bleeding, difficulty in wound healing, or produce alterations in coagulation and/or platelet aggregation. Most OAAs require perioperative monitoring, and only a small number have specific recommendations for temporary suspension before surgery. This review provides a comprehensive guide for healthcare professionals to manage OAAs during the perioperative process.

EXPERT OPINION ON DRUG SAFETY (2022)

Article Pharmacology & Pharmacy

Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease

Angela Hoyo-Munoz, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Mariana Bastos-Oreiro, Ana Herranz-Alonso, Maria Sanjurjo-Saez

Summary: This case report describes a 74-year-old female with pulmonary RDD who responded to thalidomide treatment after failing multiple previous therapies. Thalidomide induced remission in this refractory pulmonary RDD case, showing rapid onset of action and lasting responses, offering an exciting treatment option for this life-threatening condition.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)

Article Oncology

Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina Lopez-Lopez, Cristina Villanueva-Bueno, Jose Luis Revuelta-Herrero, Paula Ruiz-Briones, Beatriz Somoza-Fernandez, Ana Herranz, Maria Sanjurjo

Summary: The combination of spironolactone with abiraterone in patients with mCRPC may compromise the therapeutic effectiveness of abiraterone due to potential androgenic effects of spironolactone. Despite the potential benefits for cardiac conditions, combining spironolactone with abiraterone may lead to disease progression, as evidenced by rising PSA levels and tumor progression observed in two cases discussed. Strategies to address this interaction could involve alternative medications such as eplerenone, with a multidisciplinary approach recommended for evaluation by cardiologists and oncologists.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)

Article Oncology

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Rebecca J. Lee, Oskar Wysocki, Cong Zhou, Rohan Shotton, Ann Tivey, Louise Lever, Joshua Woodcock, Laurence Albiges, Angelos Angelakas, Dirk Arnold, Theingi Aung, Kathryn Banfill, Mark Baxter, Fabrice Barlesi, Arnaud Bayle, Benjamin Besse, Talvinder Bhogal, Hayley Boyce, Fiona Britton, Antonio Calles, Luis Castelo-Branco, Ellen Copson, Adina E. Croitoru, Sourbha S. Dani, Elena Dickens, Leonie Eastlake, Paul Fitzpatrick, Stephanie Foulon, Henrik Frederiksen, Hannah Frost, Sarju Ganatra, Spyridon Gennatas, Andreas Glenthoj, Fabio Gomes, Donna M. Graham, Christina Hague, Kevin Harrington, Michelle Harrison, Laura Horsley, Richard Hoskins, Prerana Huddar, Zoe Hudson, Lasse H. Jakobsen, Nalinie Joharatnam-Hogan, Sam Khan, Umair T. Khan, Khurum Khan, Christophe Massard, Alec Maynard, Hayley McKenzie, Olivier Michielin, Anne C. Mosenthal, Berta Obispo, Rushin Patel, George Pentheroudakis, Solange Peters, Kimberly Rieger-Christ, Timothy Robinson, Jacobo Rogado, Emanuela Romano, Michael Rowe, Marina Sekacheva, Roseleen Sheehan, Julie Stevenson, Alexander Stockdale, Anne Thomas, Lance Turtle, David Vinal, Jamie Weaver, Sophie Williams, Caroline Wilson, Carlo Palmieri, Donal Landers, Timothy Cooksley, Caroline Dive, Andre Freitas, Anne C. Armstrong

Summary: The study aimed to develop a decision support tool to assist in hospital admission decisions and predict the severity of COVID-19 in cancer patients. The results showed that the CORONET model could effectively predict the need for hospital admission and the severity of the disease, and it was validated in healthcare systems worldwide.

JCO CLINICAL CANCER INFORMATICS (2022)

Article Oncology

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

Oskar Wysocki, Cong Zhou, Jacobo Rogado, Prerana Huddar, Rohan Shotton, Ann Tivey, Laurence Albiges, Angelos Angelakas, Dirk Arnold, Theingi Aung, Kathryn Banfill, Mark Baxter, Fabrice Barlesi, Arnaud Bayle, Benjamin Besse, Talvinder Bhogal, Hayley Boyce, Fiona Britton, Antonio Calles, Luis Castelo-Branco, Ellen Copson, Adina Croitoru, Sourbha S. Dani, Elena Dickens, Leonie Eastlake, Paul Fitzpatrick, Stephanie Foulon, Henrik Frederiksen, Sarju Ganatra, Spyridon Gennatas, Andreas Glenthoj, Fabio Gomes, Donna M. Graham, Christina Hague, Kevin Harrington, Michelle Harrison, Laura Horsley, Richard Hoskins, Zoe Hudson, Lasse H. Jakobsen, Nalinie Joharatnam-Hogan, Sam Khan, Umair T. Khan, Khurum Khan, Alexandra Lewis, Christophe Massard, Alec Maynard, Hayley McKenzie, Olivier Michielin, Anne C. Mosenthal, Berta Obispo, Carlo Palmieri, Rushin Patel, George Pentheroudakis, Solange Peters, Kimberly Rieger-Christ, Timothy Robinson, Emanuela Romano, Michael Rowe, Marina Sekacheva, Roseleen Sheehan, Alexander Stockdale, Anne Thomas, Lance Turtle, David Vinal, Jamie Weaver, Sophie Williams, Caroline Wilson, Caroline Dive, Donal Landers, Timothy Cooksley, Andre Freitas, Anne C. Armstrong, Rebecca J. Lee

Summary: Indicators of COVID-19 severity in cancer patients remain predictive across different waves of the pandemic. Vaccination and steroid use have contributed to improved outcomes. The CORONET model performs well regardless of SARS-CoV-2 variants.

CANCERS (2022)

Article Oncology

Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App

Vicente Escudero-Vilaplana, Lorena Romero-Medrano, Cristina Villanueva-Bueno, Marta Rodriguez de Diago, Alberto Yanez-Montesdeoca, Roberto Collado-Borrell, Juan Jose Campana-Montes, Belen Marzal-Alfaro, Jose Luis Revuelta-Herrero, Antonio Calles, Mar Galera, Rosa alvarez, Ana Herranz, Maria Sanjurjo, Antonio Artes-Rodriguez

Summary: This project aims to develop a mobile app that continuously records smartphone parameters to assess patients' health status and quality of life. Phase 1 focused on developing the app and evaluating its usability and satisfaction among patients. The app was found to be intuitive and helpful by a majority of patients, indicating good acceptability and satisfaction.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip Patel, Hadas Gantz-Sorotsky, Alona Zer, Mor Moskovitz, Giulio Metro, Yakir Rottenberg, Antonio Calles, Maximilian Hochmair, Kristof Cuppens, Lynn Decoster, Martin Reck, Dror Limon, Estelamari Rodriguez, Christoforos Astaras, Adrienne Bettini, Simon Hafliger, Alfredo Addeo

Summary: This study aimed to collect real-world data on osimertinib treatment for patients with uncommon EGFR mutations (ucEGFRmuts). The results showed that osimertinib has a high rate of disease control, both systemically and intracranially, in patients with ucEGFRmuts. The study also identified several resistance mechanisms.

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

Thiago Quinaglia, Carlos Gongora, Magid Awadalla, Malek Z. O. Hassan, Amna Zafar, Zsofia D. Drobni, Syed S. Mahmood, Lili Zhang, Otavio R. Coelho-Filho, Giselle A. Suero-Abreu, Muhammad A. Rizvi, Gagan Sahni, Anant Mandawat, Eduardo Zatarain-Nicolas, Michael Mahmoudi, Ryan Sullivan, Sarju Ganatra, Lucie M. Heinzerling, Franck Thuny, Stephane Ederhy, Hannah K. Gilman, Supraja Sama, Sofia Nikolaidou, Ana Gonzalez Mansilla, Antonio Calles, Marcella Cabral, Francisco Fernandez-Aviles, Juan Jose Gavira, Nahikari Salterain Gonzalez, Manuel Garcia de Yebenes Castro, Ana Barac, Jonathan Afilalo, Daniel A. Zlotoff, Leyre Zubiri, Kerry L. Reynolds, Richard Devereux, Judy Hung, Michael H. Picard, Eric H. Yang, Dipti Gupta, Caroline Michel, Alexander R. Lyon, Carol L. Chen, Anju Nohria, Michael G. Fradley, Paaladinesh Thavendiranathan, Tomas G. Neilan

Summary: GCS and GRS are reduced in patients with ICI myocarditis, and the magnitude of reduction has prognostic significance.

JACC-CARDIOVASCULAR IMAGING (2022)

Article Oncology

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, Giacomo Massa, Giulio Metro, Isabelle Monnet, Patricia Gomez Iranzo, Fabrizio Tabbo, Emilio Bria, Florian Guisier, Damien Vasseur, Colin R. Lindsay, Santiago Ponce-Aix, Sophie Cousin, Fabrizio Citarella, Vincent Fallet, Jose Nicolas Minatta, Anna Eisert, Hortense de Saint Basile, Clarisse Audigier-Valette, Laura Mezquita, Antonio Calles, Giannis Mountzios, Marco Tagliamento, Jordi Remon Masip, Judith Raimbourg, Safae Terrisse, Alessandro Russo, Diego Cortinovis, Philippe Rochigneux, David James Pinato, Alessio Cortellini, Camille Leonce, Anas Gazzah, Maria-Rosa Ghigna, Roberto Ferrara, Filippo Gustavo Dall'Olio, Francesco Passiglia, Vienna Ludovini, Fabrice Barlesi, Enriqueta Felip, David Planchard, Benjamin Besse

Summary: This retrospective study analyzed 218 cases of non-small cell lung cancer (NSCLC) with RET fusion mutations and found that RET inhibitors can significantly improve patient survival, while immune checkpoint inhibitors may also be effective in some patients.

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Oncology

Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing

Miguel Garcia-Pardo, Inmaculada Aparicio, Inigo Martinez, Marta Arregui, Victoria Tirado, Mar Galera, Rosa Alvarez, Antonio Calles

Summary: Plasma-based next-generation sequencing can potentially identify additional driver alterations in patients with NSCLC compared to single-gene testing. Identifying driver alterations in plasma helps NSCLC patients receive matched targeted therapy, leading to better outcomes. Further studies are needed to explore the cost-effectiveness of liquid biopsy and novel strategies.

CLINICAL LUNG CANCER (2023)

Article Health Care Sciences & Services

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

Maria Presa, David Vicente, Antonio Calles, Laura Salinas-Ortega, Jaesh Naik, Luis F. Garcia, Javier Soto

Summary: This study evaluated the efficiency of lorlatinib compared to alectinib and brigatinib for the treatment of ALK-positive advanced NSCLC patients. The results suggest that lorlatinib may be a more efficient treatment option compared to alectinib and potentially compared to brigatinib.

CLINICOECONOMICS AND OUTCOMES RESEARCH (2023)

Meeting Abstract Oncology

Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)

Rachel E. Sanborn, Saiama N. Waqar, Byoung Chul Cho, Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E. Marmarelis, Yuichiro Ohe, Dong-Wan Kim, Antonio Calles, Joel Neal, Christina S. Baik, Pasi A. Janne, Joshua C. Curtin, Bharvin Patel, Mike Gormley, S. Martin Shreeve, Joshua M. Bauml, Roland E. Knoblauch

CANCER RESEARCH (2023)

Article Hematology

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

Inmaculada Aparicio, Patricia Iranzo, Roxana Reyes, Helena Bote, Maria Saigi, Marianela Bringas, Joaquim Bosch-Barrera, Jesus Corral, Francisco Aparisi, Jose C. Ruffinelli, Beatriz Jimenez, Yolanda Lage, Rafael Lopez-Castro, Margarita Majem, Sergio Vazquez, Angel Artal, Angel Rodriguez-Perez, Martin Lazaro-Quintela, Jose Miguel Sanchez Torres, Noemi Reguart, Marc Cucurull, Ignacio Gil-Bazo, Carlos Camps, Ernest Nadalj, Anabel del Barrio, Pilar Garrido, Manuel Domine, Rosa Alvarez, Andres J. Munoz, Antonio Calles

Summary: This study aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate. The study found that approximately 30% of patients experienced TEE, suggesting that systematic anticoagulation should be offered to these patients. However, there was no significant association between clinical and molecular features, as well as cancer treatment, and TEE occurrence.

THROMBOSIS RESEARCH (2023)

Meeting Abstract Oncology

RET-MAP: An international multi-center study of patients with advanced non-small cell lung cancer and RET fusions

Mihaela Aldea, Arianna Marinello, Wael Zrafi, Fabrizio Tabbo, Florian Guisier, Damien Vasseur, Vincent Fallet, Clarisse Audigier-Valette, Laura Mezquita, Antonio Calles, Giannis Mountzios, Marco Tagliamento, Judith Raimbourg, Safae Terrisse, Silvia Novello, Maria-Rosa Ghigna, Fabrice Barlesi, David Planchard, Benjamin Besse

CANCER RESEARCH (2022)

Meeting Abstract Oncology

Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms.

Jair Bar, Nir Peled, Shiruyeh Schokrpur, Elizabeth Dudnik, Mira Wollner, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip P. Patel, Hadas Yocheved Gantz Sorotsky, Alona Zer, Mor Moskovitz, Giulio Metro, Yakir Rottenberg, Antonio Calles, Maximilian Hochmair, Kristof Cuppens, Lynn Decoster, Alfredo Addeo

JOURNAL OF CLINICAL ONCOLOGY (2022)

No Data Available